SEARCH:   Advanced

This article was retracted on June 11, 2009. Blood, 15 February 2008, Vol. 111, No. 4, pp. 1805-1810. Prepublished online as a Blood First Edition Paper on November 8, 2007; DOI 10.1182/blood-2007-07-101212. This Article Full Text Full Text (PDF) Supplemental Appendix Retraction (v113,p6265) All Versions of this Article: blood-2007-07-101212v1 blood-2007-07-101212v2 blood-2007-07-101212v3 111/4/1805    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Abdelkefi, A. Articles by Abdeladhim, A. B. Search for Related Content PubMed PubMed Citation Articles by Abdelkefi, A. Articles by Abdeladhim, A. B. Related Collections Neoplasia Transplantation Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial Abderrahman Abdelkefi1, Saloua Ladeb1, Lamia Torjman1, Tarek Ben Othman1, Amel Lakhal1, Neila Ben Romdhane2, Halima El Omri3, Moez Elloumi4, Hatem Belaaj4, Ramzi Jeddi5, Lamia Aissaouï5, Habib Ksouri1, Assia Ben Hassen1, Fahmi Msadek6, Ali Saad7, Mohamed Hsaïri8, Kamel Boukef9, Ahlem Amouri10, Hechmi Louzir10, Koussay Dellagi10, Abdeladhim Ben Abdeladhim1, on behalf of the Tunisian Multiple Myeloma Study Group 1 Centre National de Greffe de Moelle Osseuse, Tunis; 2 Hôpital La Rabta, Tunis; 3 Hôpital Farhat Hached, Sousse; 4 Hôpital Hédi Chaker, Sfax; 5 Hôpital Aziza Othmana, Tunis; 6 Hôpital militaire, Tunis; 7 Laboratoire de cytogénétique, Hôpital Farhat Hached, Sousse; 8 Institut National de la Santé Publique, Tunis; 9 Centre National de Transfusion Sanguine, Tunis; and 10 Institut Pasteur de Tunis, Tunisia From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and younger than 60 years of age were randomly assigned to receive either tandem transplantation up front (arm A, n = 97) or one autologous stem-cell transplantation followed by a maintenance therapy with thalidomide (day + 90, 100 mg per day during 6 months) (arm B, n = 98). Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem-cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m2) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6–46 months), the 3-year overall survival was 65% in arm A and 85% in arm B (P = .04). The 3-year progression-free survival was 57% in arm A and 85% in arm B (P = .02). Up-front single autologous transplantation followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients and appears superior to tandem transplant in this setting. This study was registered at www.ClinicalTrials.gov as (NCT 00207805). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Is tandem autotransplantation necessary in myeloma? Sundar Jagannath Blood 2008 111: 1751-1752. [Full Text] [PDF] This article has been cited by other articles: S. Giralt, D. H. Vesole, G. Somlo, A. Krishnan, E. Stadtmauer, P. Mccarthy, M. C. Pasquini;, and on behalf of the Blood and Marrow Transplant Clini Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, July 1, 2009; 101(13): 964 - 964. [Full Text] [PDF] A. Kumar and B. Djulbegovic Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, July 1, 2009; 101(13): 966 - 967. [Full Text] [PDF] A. Spencer, H. M. Prince, A. W. Roberts, I. W. Prosser, K. F. Bradstock, L. Coyle, D. S. Gill, N. Horvath, J. Reynolds, and N. Kennedy Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure J. Clin. Oncol., April 10, 2009; 27(11): 1788 - 1793. [Abstract] [Full Text] [PDF] A. Kumar, M. A. Kharfan-Dabaja, A. Glasmacher, and B. Djulbegovic Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis J Natl Cancer Inst, January 21, 2009; 101(2): 100 - 106. [Abstract] [Full Text] [PDF] D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al. Thalidomide for treatment of multiple myeloma: 10 years later Blood, April 15, 2008; 111(8): 3968 - 3977. [Abstract] [Full Text] [PDF] J. Mehta One or two autografts for myeloma? Blood, April 1, 2008; 111(7): 3899 - 3900. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020